Skip to main content
Fig. 2 | BMC Pulmonary Medicine

Fig. 2

From: Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience

Fig. 2

(a) Cumulative incidence of acute exacerbation based on concomitant corticosteroid (with[w/] or without[w/o] PSL) use at antifibrotic agent initiation; (b) Cumulative incidence of acute exacerbation based on baseline corticosteroid dose at antifibrotic agent initiation; (c) Cumulative incidence of acute exacerbation based on concomitant use of proton-pump inhibitors (PPI)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us